Skip to main content

New Therapies in Relapsed Resistant Acute Lymphoblastic Leukemia

  • 5,421

    Total downloads

  • 19k

    Total views and downloads

About this Research Topic

This Research Topic is closed for submissions.

Background

Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood cancer and a leading cause of cancer-related mortality in children. Despite many major advances in the treatment of ALL, the emergence of therapy resistance and of therapy related complications remain significant challenges. Currently, about 2% of ALL patients are refractory to induction chemotherapy and 10-15% patients experience a relapse. The event-free survival of ALL patients with first relapse has not changed significantly for more than 20 years and remains poor at ~35-50%. Leukemia genomic data is vastly developing and makes new targets available.



New targeted therapy and immunotherapy are two important directions in the future to further improve the treatment result. Additionally, we must also look for new targeted therapy based on the current fast-developing leukemia genomic data, as well as looking for new immunotherapy strategies to focus on the relapsed and resistant leukemia.



We encourage prospective authors to focus their manuscripts on the initiatives around finding new mechanism for leukemia treatment resistance; developing new targeted therapy and/or immunotherapy to improve the leukemia treatment result and decrease the side effects.

Keywords: acute lymphoblastic leukemia, relapse, resistance

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Topic editors

Impact

  • 19kTopic views
  • 12kArticle views
  • 5,421Article downloads
View impact